Search
Now showing items 61-70 of 134
Optimal acquisition scheme for flow-compensated intravoxel incoherent motion diffusion-weighted imaging in the abdomen: An accurate and precise clinically feasible protocol.
(WILEY, 2020-03-01)
PURPOSE: Flow-compensated (FC) diffusion-weighted MRI (DWI) for intravoxel-incoherent motion (IVIM) modeling allows for a more detailed description of tissue microvasculature than conventional IVIM. The long acquisition ...
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
(AMER ASSOC CANCER RESEARCH, 2019-10-01)
PURPOSE: The CANON [CAVATAK in NON-muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1-targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. PATIENTS AND METHODS: ...
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
(AMER MEDICAL ASSOC, 2019-08-01)
IMPORTANCE: Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in ...
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
(BMJ PUBLISHING GROUP, 2019-08-10)
BACKGROUND: Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further development ...
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
(ELSEVIER, 2019-09-01)
OBJECTIVES: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab ...
Inflammatory microenvironment remodelling by tumour cells after radiotherapy.
(NATURE PORTFOLIO, 2020-04-01)
The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI therapies. Intrinsic ...
RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.
(WILEY, 2020-06-08)
Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti-tumour immunity but not every form of death can elicit an immune ...
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
(AMER SOC CLINICAL ONCOLOGY, 2020-08-10)
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy.
(FRONTIERS MEDIA SA, 2020-09-07)
Purpose: MR-guided Radiation Therapy (MRgRT) allows for high-precision radiotherapy under real-time MR visualization. This enables margin reduction and subsequent dose escalation which may lead to higher tumor control and ...
The role of spread through air spaces (STAS) in lung adenocarcinoma prognosis and therapeutic decision making.
(ELSEVIER IRELAND LTD, 2020-08-01)
Spread through air spaces (STAS) was included as a novel pattern of invasion in lung adenocarcinoma by the World Health Organization in 2015. Since then, multiple studies have investigated the association of STAS with ...